Overview

HOME > About us > Overview

KOSPI KOSPI-listed company (KSE: 011000) (Date of listing : 16 November 1987)

Biotech Biopharmaceutical company,
researches and develops DNA vaccines and Plasmid-based Biomedicines

cGMP CMO VGXI, Inc. is a wholly-owned subsidiary of GeneOne, which specializes in
the cGMP production of plasmids for use in human clinical trials

history
2016

07 IND approval for GLS-5700 (Zika DNA vaccine) Phase I clinical study from Health Canada
Health Products and Food Branch

06 IND approval for GLS-5700 (Zika DNA vaccine) Phase I clinical study from US FDA

2015

11IND approval for GLS-5300 (MERS DNA vaccine) Phase I clinical study from US FDA

04IND approval for INO-4212 (Ebola DNA vaccine) Phase I clinical study from US FDA

2014

05Awarded with "The Osong R&D Grand Prize" by MFDS

03VGXI, Inc. awarded as "Best CMO" by World Vaccine Congress, 7th Annual ViE Awards

03Renamed as GeneOne Life Science, Inc.

2013

10IND approval for VGX-6150 (HCV DNA vaccine) Phase I clinical study

09Selected as the Technology Innovative Company (INNOBIZ)

04VGXI, Inc. awarded as "Best CMO" by World Vaccine Congress, 6th Annual ViE Awards

2010

02Establishes corporate R&D center

2009

11IND approval for VGX-3400 (Influenza DNA vaccine) phase I clinical study

2008

05 VGXI, Inc. established as CMO manufacturing facility for cGMP plasmid DNA for use in clinical trials
- Located in The Woodlands, Texas
- Wholly owned subsidiary of VGXI International, Inc.

2005

11 Expansion into pharmaceuticals (specializing in DNA vaccine development)
Renamed as VGX International, Inc.

1976

01 Company established in Korea (Dong Yeom, Inc.)